NCT04579640: CORONAVIT

Trial of Vitamin D to Reduce Risk and Severity of COVID-19 and Other Acute Respiratory Infections

Completed Phase 3 Last updated 6 April 2022

What this trial tests

Phase 3 trial testing Vitamin D in Covid19 in 6,200 participants. Completed in 28 February 2022.

Timeline

27 October 2020

Primary endpoint
17 June 2021

28 February 2022

Quick facts

Lead sponsor	Queen Mary University of London
Phase	Phase 3
Status	Completed
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	none
Primary purpose	prevention
Enrollment	6,200
Start date	27 October 2020
Primary completion	17 June 2021
Estimated completion	28 February 2022
Sites	1 location across United Kingdom

Drugs / interventions tested

• Vitamin D

Conditions studied

• Covid19 — all drugs for Covid19 →
• Acute Respiratory Tract Infection — all drugs for Acute Respiratory Tract Infection →

Sponsor

Queen Mary University of London

Who can join

16 and older, any sex, with Covid19 or Acute Respiratory Tract Infection. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

CORONAVIT is an open-label, phase 3, randomised clinical trial testing whether implementation of a test-and-treat approach to correction of sub-optimal vitamin D status results in reduced risk and/or severity of COVID-19 and other acute respiratory infections.

Publications & conference data

8 peer-reviewed publications reference this trial (live from Europe PMC):

1. An update on drugs with therapeutic potential for SARS-CoV-2 (COVID-19) treatment.
   Drożdżal S, Rosik J, Lechowicz K, Machaj F, et al · · 2021 · cited 186× · PMID 34991982 · DOI 10.1016/j.drup.2021.100794
2. Vitamin D supplementation for the treatment of COVID-19: a living systematic review.
   Stroehlein JK, Wallqvist J, Iannizzi C, Mikolajewska A, et al · · 2021 · cited 85× · PMID 34029377 · DOI 10.1002/14651858.cd015043
3. Effect of a test-and-treat approach to vitamin D supplementation on risk of all cause acute respiratory tract infection and covid-19: phase 3 randomised controlled trial (CORONAVIT).
   Jolliffe DA, Holt H, Greenig M, Talaei M, et al · · 2022 · cited 73× · PMID 36215226 · DOI 10.1136/bmj-2022-071230
4. Micronutrients, Phytochemicals and Mediterranean Diet: A Potential Protective Role against COVID-19 through Modulation of PAF Actions and Metabolism.
   Detopoulou P, Demopoulos CA, Antonopoulou S. · · 2021 · cited 52× · PMID 33573169 · DOI 10.3390/nu13020462
5. Vitamin D and COVID-19: evidence and recommendations for supplementation.
   Griffin G, Hewison M, Hopkin J, Kenny R, et al · · 2020 · cited 47× · PMID 33489300 · DOI 10.1098/rsos.201912
6. Vitamin D Supplementation Does Not Influence SARS-CoV-2 Vaccine Efficacy or Immunogenicity: Sub-Studies Nested within the CORONAVIT Randomised Controlled Trial.
   Jolliffe DA, Vivaldi G, Chambers ES, Cai W, et al · · 2022 · cited 26× · PMID 36145196 · DOI 10.3390/nu14183821
7. The Role of Vitamin D in COVID-19 and the Impact of Pandemic Restrictions on Vitamin D Blood Content.
   Tomaszewska A, Rustecka A, Lipińska-Opałka A, Piprek RP, et al · · 2022 · cited 26× · PMID 35264968 · DOI 10.3389/fphar.2022.836738
8. Notable Developments for Vitamin D Amid the COVID-19 Pandemic, but Caution Warranted Overall: A Narrative Review.
   Lordan R. · · 2021 · cited 26× · PMID 33652653 · DOI 10.3390/nu13030740